FDA close out note lifts Claris in India
This article was originally published in Scrip
Shares of Claris Lifesciences surged on the Bombay Stock Exchange (BSE) after the company drew attention to a close out letter from US FDA, suggesting that the Indian firm may have successfully addressed concerns over deficiencies in current good manufacturing practices (cGMP) at its facility in Ahmedabad.
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.